Mammoth Biosciences
Mammoth Biosciences is a Gene & Genome Editing Platforms company founded in 2017 and based in Brisbane, United States. It has raised $303M in total funding, most recently a Series D in 2021 at a $1B valuation.
Co-founded in 2017 by CRISPR pioneer Jennifer Doudna with Janice Chen, Lucas Harrington, and Trevor Martin, Mammoth Biosciences engineers ultra-small Cas enzymes — including CasPhi (Cas-Phi/Cas12j) and the ~450-amino-acid NanoCas — that are compact enough to be packaged into single AAV vectors for in vivo delivery beyond the liver. The same protein-discovery toolbox powers the DETECTR CRISPR diagnostics platform. The company reached unicorn status with a $150M Series D in 2021 (Redmile Group lead) and has signed enzyme-access deals, including a 2024 partnership with Regeneron worth up to $100M upfront for AAV-delivered editing.
Its compact Cas enzymes are a leading answer to the central delivery bottleneck in in vivo gene editing.
mammothbiosci.com ↗·Gene & Genome Editing Platforms·
United States·private 
